Johnson And Johnson Faces Fresh Talc Verdict As Pipeline Story Evolves [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Philadelphia jury orders Johnson & Johnson to pay damages in a talc related ovarian cancer case, the first plaintiff win there since litigation restarted. Verdict comes after prior bankruptcy efforts to contain tens of thousands of talc lawsuits were halted, putting fresh focus on product liability risk. Bayer files a separate lawsuit over Johnson & Johnson prostate cancer drug marketing practices. Company reports recent R&D milestones in oncology and autoimmune disease treatments. For investors watching Johnson & Johnson (NYSE:JNJ), the new Philadelphia talc verdict brings legal risk back into sharp focus just as the stock trades around $243.47. The company has a value score of 4 and has seen returns of 83.2% over 5 years, including 17.4% year to date and 52.8% over the past year. This sets a contrasting backdrop to renewed litigation headlines. Looking ahead, the
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- AstraZeneca News On Cancer And Asthma Raises New Questions For Investors [Yahoo! Finance]Yahoo! Finance
- Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer [Yahoo! Finance]Yahoo! Finance
- Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancerPR Newswire
- Are You Looking for a High-Growth Dividend Stock? [Yahoo! Finance]Yahoo! Finance
- Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 1/21/26 - Beat
JNJ
Sec Filings
- 2/23/26 - Form 4
- 2/20/26 - Form 144
- 2/18/26 - Form 4
- JNJ's page on the SEC website